Mesoblast Ltd (MESO)

Mesoblast Ltd (MESO) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $1.7B; returns 1 day -2.2%, 1 week -7.5%, 1 year -28.2%.

Mesoblast Limited is an Australia-based biotechnology company focused on developing and commercializing allogeneic cellular medicines to treat inflammatory diseases. Its primary product, Ryoncil (remestemcel-L-rknd), is the first FDA-approved mesenchymal stromal cell (MSC) therapy, indicated for steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children under 12.

Groups MESO belongs to

• Biotechnology
• Regenerative Medicine
• Biopharmaceutical
• Commercial Stage Biotech
• Healthcare
• Chronic Inflammatory Diseases
• Biologics
• Pharmaceuticals
• Rare Diseases

MESO financial model: income statement, cash flow and balance sheet